Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study - PubMed (original) (raw)
. 2008 Jan 2;100(1):32-40.
doi: 10.1093/jnci/djm267. Epub 2007 Dec 25.
Leslie Bernstein, Jørgen H Olsen, Lene Mellemkjaer, Robert W Haile, Charles F Lynch, Kathleen E Malone, Hoda Anton-Culver, Jane Christensen, Bryan Langholz, Duncan C Thomas, Colin B Begg, Marinela Capanu, Bent Ejlertsen, Marilyn Stovall, John D Boice Jr, Roy E Shore; Women's Environment, Cancer and Radiation Epidemiology Study Collaborative Group; Jonine L Bernstein
Affiliations
- PMID: 18159070
- DOI: 10.1093/jnci/djm267
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study
Lisbeth Bertelsen et al. J Natl Cancer Inst. 2008.
Abstract
Background: Results from randomized trials indicate that treatment with tamoxifen or chemotherapy for primary breast cancer reduces the risk for contralateral breast cancer. However, less is known about how long the risk is reduced and the impact of factors such as age and menopausal status.
Methods: The study included 634 women with contralateral breast cancer (case patients) and 1158 women with unilateral breast cancer (control subjects) from the Women's Environment, Cancer and Radiation Epidemiology Study. The women were younger than age 55 when they were first diagnosed with breast cancer during 1985-1999. Rate ratios (RRs) and 95% confidence intervals (CIs) for contralateral breast cancer after treatment with chemotherapy or tamoxifen were assessed by multivariable adjusted conditional logistic regression analyses.
Results: Chemotherapy was associated with a lower risk for contralateral breast cancer (RR = 0.57, 95% CI = 0.42 to 0.75) than no chemotherapy. A statistically significant association between chemotherapy and reduced risk for contralateral breast cancer persisted up to 10 years after the first breast cancer diagnosis and was stronger among women who became postmenopausal within 1 year of the first breast cancer diagnosis (RR = 0.28, 95% CI = 0.11 to 0.76). Tamoxifen use was also associated with reduced risk for contralateral breast cancer (RR = 0.66, 95% CI = 0.50 to 0.88) compared with no use, and the association was statistically significant for 5 years after the first diagnosis.
Conclusion: The associations between chemotherapy and tamoxifen treatment and reduced risk for contralateral breast cancer appear to continue for 10 and 5 years, respectively, after the initial breast cancer is diagnosed. Ovarian suppression may have a role in the association between chemotherapy and reduced risk for contralateral breast cancer.
Similar articles
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2005 May 14-20;365(9472):1687-717. doi: 10.1016/S0140-6736(05)66544-0. Lancet. 2005. PMID: 15894097 - Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N. Swain SM, et al. J Natl Cancer Inst. 2004 Apr 7;96(7):516-23. doi: 10.1093/jnci/djh097. J Natl Cancer Inst. 2004. PMID: 15069113 - Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer.
Di Leo A, Buyse M. Di Leo A, et al. J Clin Oncol. 2002 Apr 1;20(7):1954-5. doi: 10.1200/JCO.2002.20.7.1954. J Clin Oncol. 2002. PMID: 11919262 No abstract available. - Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
Pritchard KI. Pritchard KI. Oncology (Williston Park). 2009 Jan;23(1):27-33. Oncology (Williston Park). 2009. PMID: 19283918 Review. - Adjuvant treatment in node-negative, postmenopausal breast cancer.
Hutchins LF, Arick CL. Hutchins LF, et al. Cancer Invest. 2001;19(7):706-22. doi: 10.1081/cnv-100106146. Cancer Invest. 2001. PMID: 11577812 Review. No abstract available.
Cited by
- Adjuvant endocrine therapy and risk of contralateral breast cancer: a systematic review and meta-analysis of observational studies.
Ghosh R, Pfeiffer RM, Roberts S, Gierach GL, Dallal CM. Ghosh R, et al. Cancer Causes Control. 2024 Oct 9. doi: 10.1007/s10552-024-01900-5. Online ahead of print. Cancer Causes Control. 2024. PMID: 39382775 Review. - Trends in Radiation Dose to the Contralateral Breast During Breast Cancer Radiation Therapy.
Watt GP, Smith SA, Howell RM, Pérez-Andújar A, Reiner AS, Cerviño L, McCormick B, Hess D, Knight JA, Malone KE, John EM, Bernstein L, Lynch CF, Mellemkjær L, Shore RE, Liang X, Woods M, Boice JD, Dauer LT, Bernstein JL. Watt GP, et al. Radiat Res. 2023 Oct 1;200(4):331-339. doi: 10.1667/RADE-23-00014.1. Radiat Res. 2023. PMID: 37590492 Free PMC article. - Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort.
Ramin C, Veiga LHS, Vo JB, Curtis RE, Bodelon C, Aiello Bowles EJ, Buist DSM, Weinmann S, Feigelson HS, Gierach GL, Berrington de Gonzalez A. Ramin C, et al. Breast Cancer Res. 2023 May 3;25(1):50. doi: 10.1186/s13058-023-01647-y. Breast Cancer Res. 2023. PMID: 37138341 Free PMC article. - The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in _BRCA1/BRCA2/PALB2_-Negative Women.
Larionov A, Fewings E, Redman J, Goldgraben M, Clark G, Boice J, Concannon P, Bernstein J, Conti DV, The Wecare Study Collaborative Group, Tischkowitz M. Larionov A, et al. Cancers (Basel). 2023 Jan 8;15(2):415. doi: 10.3390/cancers15020415. Cancers (Basel). 2023. PMID: 36672364 Free PMC article. - Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
Chen F, Park SL, Wilkens LR, Wan P, Hart SN, Hu C, Yadav S, Couch FJ, Conti DV, de Smith AJ, Haiman CA. Chen F, et al. Cancer Res. 2022 Sep 16;82(18):3201-3208. doi: 10.1158/0008-5472.CAN-21-4461. Cancer Res. 2022. PMID: 35834270 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
- U55/CCR921930-02/PHS HHS/United States
- R01 CA114236/CA/NCI NIH HHS/United States
- U01 CA083178/CA/NCI NIH HHS/United States
- N01 PC35143/PC/NCI NIH HHS/United States
- N01 PC35139/PC/NCI NIH HHS/United States
- R01 CA129639/CA/NCI NIH HHS/United States
- N01 PC35142/PC/NCI NIH HHS/United States
- N02 PC15105/PC/NCI NIH HHS/United States
- R01 CA097397/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical